Veliparib

Published

dm+d

Unassigned

New Medicines

Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel

Information

New molecular entity
AbbVie
AbbVie

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Mar 21Development discontinued. AbbVie will not proceeding with regulatory filings for veliparib [7].

Category

Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor
In 2013 there were 7,284 new cases. In 2014 there were 4,128 deaths from ovarian cancer [1].
Serous epithelial ovarian, fallopian tube or primary peritoneal cancer with BRCA1 mutation, stage II or IV high-grade - first-line with carboplatin and paclitaxel
Oral

Further information

Yes

Evidence based evaluations

HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer - first to third-line in combination with carboplatin and paclitaxel

Information

New molecular entity
AbbVie
AbbVie

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Aug 21Development was discontinued in March 2021 [10].
Apr 21Company is no longer pursuing a Marketing Authorisation Application from the EMA or MHRA for this indication at this time [9].

Category

Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor
Approximately 5% of patients present with metastatic breast cancer, and around 30% of people who present with localised disease will later develop metastases. About 70-80% of those with metastatic disease have HER2 negative tumours [1].
HER2-negative metastatic or locally advanced unresectable BRCA-associated breast cancer - first to third-line in combination with carboplatin and paclitaxel
Oral

Further information

Yes

Evidence based evaluations